Fly News Breaks for January 22, 2020
Jan 22, 2020 | 07:39 EDT
Veru shares are up 117% from January 12, 2019, but the stock "is in the early innings of reflecting the true value that could be unlocked in the company's pipeline this year," Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. He believes the shares are likely to "continue to reward investors this year." Upside for the stock will be driven by a positive Phase 1b data readout from VERU-111 in prostate cancer, a full dataset from Zuclomiphene citrate, interim looks on the three Phase 2 VERU-111 cancer trials, submission of IND on VERU-100, NDA submission of Tadfin, and continued growth of the company's base business, Folkes contends. He keeps an Overweight rating on Veru with a $6 price target.
News For VERU From the Last 2 Days
There are no results for your query VERU